氨酸血管压素在ST-升高心肌梗塞后的微血管功能障碍中起作用
Ayman Al-Atta1,2, Luke Spray1,2, Ashfaq Mohammed1
1Freeman Hospital Newcastle upon Tyne United Kingdom.
Journal of the American Heart Association
|September 8, 2023
概括
在ST升高心肌梗塞 (STEMI) 患者中持续升高的可佩表明冠状动脉微血管功能障碍 (CMD). 氨酸压缩素 (AVP) 可能导致CMD,这表明AVP受体对抗剂是潜在的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 生物标志物 生物标志物
背景情况:
- 冠状动脉微血管功能障碍 (CMD) 是ST升高后心肌梗塞 (STEMI) 死亡率的预测因素.
- 氨酸血管压素 (AVP) 在人类CMD中的作用仍未得到充分研究,没有研究将其与侵入性CMD措施联系起来.
研究的目的:
- 在STEMI患者中,调查阿尔金因压素 (AVP) 和冠状动脉微血管功能障碍 (CMD) 的侵入性措施之间的关联.
- 探索血清中可佩水平之间的关系,AVP的标志物,和CMD参数后初级皮肤穿冠状动脉干预 (PPCI).
主要方法:
- 在55名STEMI患者中使用PPCI后微循环阻力指数 (IMR) 进行CMD的侵入性评估.
- 心脏磁共振 (CMR) 图像测量45名STEMI/PPCI患者的心脏病发作大小和微血管阻塞.
- 在所有STEMI患者中,在PPCI前后的多个时间点测量血清可佩丁水平.
主要成果:
- 血清可佩素水平从再输血前显著下降到PPCI后24小时.
- 在PPCI后24小时持续升高的可佩与更高的微循环阻力指数 (IMR) 相相关,表明CMD.
- 在CMR上,没有发现可佩素水平与心脏病发作大小或微血管阻塞之间的显著关联.
结论:
- 在STEMI后24小时持续升高的可佩水平与CMD有关.
- 这些发现表明,氨酸血管压素 (AVP) 在STEMI后调解微血管功能障碍方面可能发挥作用.
- AVP受体对抗剂可能为患有CMD的STEMI患者提供一种新的治疗策略.
更多相关视频
08:01Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
8.2K
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.9K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
01:23Antihypertensive Drugs: Vasodilators
565
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
565
01:25Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
687
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687